CRUK CENTRE FOR DRUG DEVELOPMENT

SMALL MOLECULES

					DEVELOPMENT STAGE					
AGENT/TRIAL	TARGET/ TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	PROJECT INITIATION	EXPLORAT-ORY	PRE-CLINICAL	TRIAL SET UP	PHASE I/II	PHASE II
ORIC259	CIP2A	ORIC	Solid	First in class	⇢	⇢				
BT1718	MT1-MMP	Bicycle	Solid, lung	First in class (closed)	⇢	⇢	⇢	⇢	⇢	
HTL0039732	EP4	NXera	Solid, colorectal, prostate, gastric, oesophageal, renal	First in human	⇢	⇢	⇢	⇢	⇢	
LY3143921	Cdc7	Lilly	Solid, colorectal, ovarian, lung	First in human (closed)	⇢	⇢	⇢	⇢	⇢	
TT702 (CURATE)	adenosine $A_{2B}R$	TEON THERAPEUTICS, INC.	Solid	First in human	⇢	⇢	⇢	⇢	⇢	
DETERMINE - Alectinib - Dabrafenib/ Trametinib - Entrectinib	ALK, BRAF, MEK, ROS1, TKI, TRK	MANCHESTER 1824 The University of Manchester Roche NOVARTIS	Rare adult, paediatric & TYA cancers	Phase II Phase II combination Phase II	⇢	⇢	⇢	⇢	⇢	⇢
DETERMINE - Capmatinib - Vemurafenib/ Cobimetinib	BRAF, cMET, HGFR, MAP, MEK	MANCHESTER 1824 The University of Manchester Roche NOVARTIS	Rare adult cancers	Phase II Phase II combi (closed)	⇢	⇢	⇢	⇢	⇢	⇢

CRUK CENTRE FOR DRUG DEVELOPMENT
BIOLOGICS

					DEVELOPMENT STAGE					
AGENT/TRIAL	TARGET/ TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	PROJECT INITIATION	EXPLORAT-ORY	PRE-CLINICAL	TRIAL SET UP	PHASE I/II	PHASE II
ALETA001	Protein CD19, CD20	ALETA BIOTHERAPEUTICS	Lymphoma	First in class	⇢	⇢	⇢	⇢	⇢	
HMBD001	Antibody Her3	Hummingbird Bioscience	Solid, prostate	First in human (closed)	⇢	⇢	⇢	⇢	⇢	
KJ103	Antibody TROP2	木曽路 KisoJi	Solid, breast, lung, renal, oral	First in class	⇢	⇢	⇢	⇢	⇢	
NVG222 haematological	BITE ROR1, CD3	NOVALGEN	Lymphoma	First in human	⇢	⇢	⇢	⇢	⇢	
NVG222 solid	BITE ROR1, CD3	NOVALGEN	Solid	First in indication	⇢	⇢	⇢	⇢	⇢	
UCB4594	Antibody HLA-G1	ucb	Solid, renal	First in human	⇢	⇢	⇢	⇢	⇢	
VTP600 (MAGE)	Vaccine MAGE3, NY-ESO-1	BARINTHUS BIOTHERAPEUTICS	Lung	First in human (closed)	⇢	⇢	⇢	⇢	⇢	
CY101 (CLARITY)	Peptide β-catenin, WNT	cytovation; NORWEGIAN CANCER SOCIETY	Adenocortical carcinoma	First in class Phase II	⇢	⇢	⇢	⇢	⇢	⇢
DETERMINE - Atezolizumab - Trastuzumab/ Pertuzumab	Antibodies PDL1 HER2	MANCHESTER 1824 The University of Manchester; Roche	Rare adult, paediatric & TYA cancers	Phase II Phase II combination	⇢ ⇢	⇢ ⇢	⇢ ⇢	⇢ ⇢	⇢ ⇢	⇢ ⇢
Ginisortamab (UCB6114)	Antibody Gremlin1	ucb; NORWEGIAN CANCER SOCIETY	Pancreatic	First in class Phase II	⇢	⇢	⇢	⇢	⇢	⇢